Human TrkB, His tag
$168.00 - $448.00
$560.00
Initially identified as an oncogenic fusion in 1982, the Trk family has recently regained attention due to its implications in human cancers. This resurgence stems from the discovery of gene fusions and other oncogenic alterations involving NTRK1 (TrkA), NTRK2 (TrkB), and NTRK3 (TrkC) in various tumor types. Clinical trials investigating Trk inhibitors have shown promising preliminary results, indicating their potential in shrinking human tumors.
Beyond oncology, TrkB and its ligand BDNF have been linked to both normal brain function and the pathophysiology of Alzheimer’s disease (AD) and other neurodegenerative disorders. This association underscores the diverse roles of TrkB signaling in neurological health and disease progression.
All products have special prices for bulk purchase, please contact us for more details if required.
Cat. No.: HTRKBH-25 (for 25μg)
Cat. No.: HTRKBH-50 (for 50μg)
Cat. No.: HTRKBH-100 (for 100μg)
Description
Tropomyosin receptor kinase B (TrkB) serves as the high-affinity catalytic receptor for several neurotrophins, which are small protein growth factors pivotal in inducing the survival and differentiation of distinct cell populations. The neurotrophins that activate TrkB include Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4 (NT-4), and neurotrophin-3 (NT-3).
Initially identified as an oncogenic fusion in 1982, the Trk family has recently regained attention due to its implications in human cancers. This resurgence stems from the discovery of gene fusions and other oncogenic alterations involving NTRK1 (TrkA), NTRK2 (TrkB), and NTRK3 (TrkC) in various tumor types. Clinical trials investigating Trk inhibitors have shown promising preliminary results, indicating their potential in shrinking human tumors.
Beyond oncology, TrkB and its ligand BDNF have been linked to both normal brain function and the pathophysiology of Alzheimer’s disease (AD) and other neurodegenerative disorders. This association underscores the diverse roles of TrkB signaling in neurological health and disease progression.
Species
Human
Molecular Alias
GP145-TrkB (Trk-B), Neurotrophic tyrosine kinase receptor type 2, TrkB tyrosine kinase, Tropomyosin-related kinase B, NTRK2
Accession
Q16620
Expression Sequence
Protein sequence(Q16620, Trp230-His430, with C-10*His)
WDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHGGGGSHHHHHHHHHH
Expression Host
HEK293
Molecular Weight
Theoretical: 24kDa
Actual: 35-45kDa
Purity
>95% by SDS-PAGE
Endotoxin content
<1 EU/μg
Label
Unconjugated
Tag
His Tag
Form
Lyophilized Powder
Buffer System
Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4.
Reconstitution Method
Reconstitute at no more than 1 mg/mL according to the size in deionized water after rapid centrifugation.
Storage Conditions
12 months from the date of receipt when stored at -20 to -70 °C as supplied.
6 months at -20 to -70 °C under sterile conditions after reconstitution.
1 week at 2 to 8 °C under sterile conditions after reconstitution.
Please avoid repeated freeze-thaw cycles.